Appendix • Noninvasive Tests to Support Disease Monitoring

Noninvasive Biomarkers to Assess Risk of Clinical Outcomes

Longitudinal ELF, VCTE, and MRE thresholds linked to cirrhosis progression, hepatic decompensation, hepatocellular carcinoma, and survival.

What This Means for Patients

Noninvasive tests do more than stage your liver on day one: tracking how they move over time tells you and your care team where your risk is headed. For instance, an ELF score at or above 9.8, a baseline FibroScan stiffness at or above 16.6 kPa, a 20% jump in FibroScan kPa, or a 15% rise in MRE stiffness all signal meaningfully higher odds of progressing toward cirrhosis or liver complications over the next 1.5 to 4 years. That also works in your favor: stabilizing or lowering those numbers is a real, measurable sign that your treatment plan is protecting your liver.

Prognostic Thresholds Associated With Progression and Liver-Related Outcomes

Biomarker Criteria Outcome Assessed Comparative Risk Median Follow-Up
ELF™ ≥9.76 Progression to cirrhosis 22% 2.4 years
≥9.8 Hepatic decompensation, HCC, or PHTN 25% vs 2.9% 4.2 years
≥11.27 Hepatic decompensation, MELD ≥15 or ≥2-point increase in CP score, or death 19% 2.4 years
LSM by VCTE™ Baseline kPa ≥16.6 Progression to cirrhosis 31.1% vs 9.1% 1.4 years
≥5% kPa and ≥20% increase in kPa Progression to cirrhosis 22.2% vs 14% 1.4 years
Baseline kPa ≥13 Hepatic decompensation, HCC, or PHTN 17% vs 0.5% 4.2 years
Baseline kPa ≥21 Hepatic decompensation 14% vs 2% 3 years
Baseline kPa ≥30.7 Hepatic decompensation, OLT, MELD ≥15, or death 11.1% vs 1.4% 1.4 years
Per 1 unit increase in kPa Hepatic decompensation, HCC, or PHTN 7% increase in hazard N/A
>20% increase in kPa Hepatic decompensation 14.4% vs 10% 3 years
>20% increase in kPa HCC 6.7% vs 5.8% 3 years
>20% increase in kPa Liver-related death 10.6% vs 9.8% 3 years
>20% increase in kPa Overall death 7.7% vs 6.5% 3 years
LSM by MRE ≥15% increase in kPa Fibrosis progression ≥1 stage 47.1% vs 20% 1.4 years
Baseline kPa >5 vs <3.63 Hepatic decompensation, HCC, or death 25% vs 0% 3 years
Tracking Positive Treatment Response on MASH Therapy (6–12 Months): Beyond predicting progression risk, longitudinal NITs measure positive biological response to resmetirom, semaglutide 2.4 mg, or structured weight loss. Validated responder targets include an MRI-PDFF relative fat reduction ≥30%, VCTE stiffness drop ≥20%–25%, ALT drop ≥17 U/L, ELF™ drop ≥0.5 units, or mpMRI cT1 drop ≥80 ms — see MASH Therapy Eligibility & Treatment Response for full details.